GlassScriptPhysician profile
David M Berlach
NPI 1811275514
$5,959.05
in general payments reported to CMS, 2019-2025
27 companies · $2,273 in 2025
The $2,273 reported for 2025 was more than what 91% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.54 · 2021: $128 · 2022: $67.11 · 2023: $863 · 2024: $2,549 · 2025: $2,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,286 · Travel and Lodging: $1,699 · Consulting Fee: $850 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,285.89 |
| Travel and Lodging | $1,699.04 |
| Consulting Fee | $850.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $850.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Molecular Systems, INC. | $1,700.00 | 2024 | |
| Visionrt, INC. | $1,318.98 | 2025 | |
| Siemens Medical Solutions USA, INC. | $569.07 | 2023 | Varian Ethos Treatment Planning |
| Janssen Biotech, INC. | $321.08 | 2023-2025 | Erleada, Akeega, Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $244.71 | 2024-2025 | Ninlaro, Vpriv, Iclusig |
| Merck Sharp & Dohme LLC | $226.53 | 2021-2025 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $177.71 | 2025 | |
| Icotec Medical INC. | $171.12 | 2024 | Vader Pedicle System |
| Mevion_medical_systems_inc | $171.10 | 2023 | Pts250 |
| Eisai INC. | $132.32 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.63 | 2019-2025 | |
| Agios Pharmaceuticals, INC. | $101.57 | 2024-2025 | Pyrukynd |
| Astrazeneca Pharmaceuticals LP | $87.89 | 2021-2024 | Imjudo |
| Deciphera Pharmaceuticals INC. | $82.42 | 2024-2025 | Qinlock, Romvimza, Tgct |
| Genmab U.S., INC. | $80.24 | 2025 | Tivdak |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $73.94 | 2024 | |
| Nuvation Bio INC. | $57.71 | 2025 | Ibtrozi |
| Puma Biotechnology, INC. | $47.56 | 2021 | |
| Servier Pharmaceuticals LLC | $39.78 | 2025 | |
| Blueprint Medicines Corporation | $36.15 | 2024 | Ayvakit |
| Daiichi Sankyo INC. | $35.98 | 2019-2025 | Enhertu |
| Dendreon Pharmaceuticals LLC | $33.83 | 2025 | Provenge |
| Syndax Pharmaceuticals, INC. | $33.28 | 2025 | Revuforj |
| Karyopharm Therapeutics INC. | $29.94 | 2024 | Xpovio |
| Tactile Systems Technology INC | $28.32 | 2025 | Flexitouch Plus, Nimbl |
| Tesaro, INC. | $28.00 | 2019 | |
| Gilead Sciences, INC. | $18.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Berlach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.